Gary R. Sitko

1.1k total citations
29 papers, 756 citations indexed

About

Gary R. Sitko is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Gary R. Sitko has authored 29 papers receiving a total of 756 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 15 papers in Cardiology and Cardiovascular Medicine and 10 papers in Surgery. Recurrent topics in Gary R. Sitko's work include Platelet Disorders and Treatments (16 papers), Antiplatelet Therapy and Cardiovascular Diseases (12 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (9 papers). Gary R. Sitko is often cited by papers focused on Platelet Disorders and Treatments (16 papers), Antiplatelet Therapy and Cardiovascular Diseases (12 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (9 papers). Gary R. Sitko collaborates with scholars based in United States and United Kingdom. Gary R. Sitko's co-authors include Joseph J. Lynch, Jacquelynn J. Cook, Denise Ramjit, Maria T. Stranieri, Marie A. Holahan, Inez I. Stabilito, Robert J. Lynch, G P Vlasuk, Robert J. Gould and Michael J. Mellott and has published in prestigious journals such as Circulation, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Gary R. Sitko

28 papers receiving 695 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary R. Sitko United States	16	369	261	149	125	122	29	756
Maria T. Stranieri United States	16	272 0.7×	137 0.5×	205 1.4×	166 1.3×	85 0.7×	26	642
Patricia W. Bedard United States	10	139 0.4×	81 0.3×	173 1.2×	162 1.3×	57 0.5×	10	532
Tomio Yamazaki Japan	17	466 1.3×	39 0.1×	113 0.8×	163 1.3×	51 0.4×	44	761
Leo Alig Switzerland	5	150 0.4×	67 0.3×	71 0.5×	112 0.9×	51 0.4×	6	352
Timothy Mather United States	15	298 0.8×	69 0.3×	13 0.1×	231 1.8×	43 0.4×	17	616
Leslie A. Bush United States	14	554 1.5×	67 0.3×	17 0.1×	297 2.4×	40 0.3×	19	826
Masaharu Aritomi Japan	11	128 0.3×	50 0.2×	16 0.1×	177 1.4×	28 0.2×	13	437
Richard Faint United Kingdom	13	181 0.5×	33 0.1×	87 0.6×	193 1.5×	30 0.2×	17	556
Alexander Tischer United States	15	217 0.6×	27 0.1×	20 0.1×	317 2.5×	45 0.4×	42	661
Karine Aupeix France	8	69 0.2×	17 0.1×	32 0.2×	266 2.1×	111 0.9×	8	480

Countries citing papers authored by Gary R. Sitko

Since Specialization

Citations

This map shows the geographic impact of Gary R. Sitko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary R. Sitko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary R. Sitko more than expected).

Fields of papers citing papers by Gary R. Sitko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary R. Sitko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary R. Sitko. The network helps show where Gary R. Sitko may publish in the future.

Co-authorship network of co-authors of Gary R. Sitko

This figure shows the co-authorship network connecting the top 25 collaborators of Gary R. Sitko. A scholar is included among the top collaborators of Gary R. Sitko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary R. Sitko. Gary R. Sitko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Wickham, L. Alexandra, Gary R. Sitko, Steven D.E. Fried, et al.. (2016). Differential anti-thrombotic benefit and bleeding risk profiles of antagonists of protease-activated receptor 1 and 4 in Cynomolgus Macaques. Thrombosis Research. 145. 133–139.

2.

Cai, Tian‐Quan, L. Alexandra Wickham, Gary R. Sitko, et al.. (2015). Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist. European Journal of Pharmacology. 758. 107–114. 13 indexed citations

3.

Michener, Maria S., Marie A. Holahan, Gary R. Sitko, et al.. (2006). P2–069: Nonhuman primate model for prediction of human Aβ effects. Targeting γ–secretase: Effects of enzyme inhibition vs. modulation of cleavage specificity on CSF and plasma Aβ in conscious rhesus monkeys. Alzheimer s & Dementia. 2(3S_Part_9). 4 indexed citations

4.

Rose, Mark J., et al.. (2005). Determination of potato carboxypeptidase inhibitor in African Green Monkey plasma using 96-well SPE and LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 38(4). 695–702. 8 indexed citations

5.

Barrow, James C., Philippe G. Nantermet, Shaun R. Stauffer, et al.. (2003). Synthesis and Evaluation of Imidazole Acetic Acid Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor as Novel Antithrombotics. Journal of Medicinal Chemistry. 46(25). 5294–5297. 36 indexed citations

6.

Egbertson, Melissa S., Jacquelynn J. Cook, Bohumil Bednář, et al.. (1999). Non-Peptide GPIIb/IIIa Inhibitors. 20. Centrally Constrained Thienothiophene α-Sulfonamides Are Potent, Long Acting in Vivo Inhibitors of Platelet Aggregation. Journal of Medicinal Chemistry. 42(19). 4014–4014. 2 indexed citations

7.

Egbertson, Melissa S., Jacquelynn J. Cook, Bohumil Bednář, et al.. (1999). Non-Peptide GPIIb/IIIa Inhibitors. 20. Centrally Constrained Thienothiophene α-Sulfonamides Are Potent, Long Acting in Vivo Inhibitors of Platelet Aggregation. Journal of Medicinal Chemistry. 42(13). 2409–2421. 41 indexed citations

8.

Prueksaritanont, Thomayant, Maria T. Stranieri, Elizabeth Hand, et al.. (1997). Effects of pentobarbital on pharmacokinetics and pharmacodynamics of a potent fibrinogen receptor antagonist, L-734 217, in dogs. Biopharmaceutics & Drug Disposition. 18(8). 649–663. 3 indexed citations

9.

Cook, Jacquelynn J., Gary R. Sitko, Marie A. Holahan, et al.. (1997). Nonpeptide Glycoprotein IIb/IIIa Inhibitors. 15. Antithrombotic Efficacy of L-738,167, a Long-Acting GPIIb/IIIa Antagonist, Correlates with Inhibition of Adenosine Diphosphate-Induced Platelet Aggregation but not with Bleeding Time Prolongation. Journal of Pharmacology and Experimental Therapeutics. 281(2). 677–689. 12 indexed citations

10.

Hutchinson, John H., Jacquelynn J. Cook, Karen M. Brashear, et al.. (1997). ChemInform Abstract: Non‐Peptide Glycoprotein IIb/IIIa Antagonists. Part 11. Design and in vivo Evaluation of 3,4‐Dihydro‐1(1H)‐isoquinolinone‐Based Antagonists and Ethyl Ester Prodrugs.. ChemInform. 28(8). 1 indexed citations

11.

Prugh, John D., Robert J. Gould, Robert J. Lynch, et al.. (1997). Nonpeptide GPIIB/IIIA inhibitors. 16. Thieno[2,3-b]thiophene α-sulfonamides are potent inhibitors of platelet aggregation. Bioorganic & Medicinal Chemistry Letters. 7(7). 865–870. 9 indexed citations

12.

Cook, Jacquelynn J., Gary R. Sitko, Marie A. Holahan, et al.. (1997). Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.. PubMed. 96(3). 949–58. 13 indexed citations

13.

Cook, Jacquelynn J., Marie A. Holahan, Denise Ramjit, et al.. (1996). Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.. Journal of Pharmacology and Experimental Therapeutics. 278(1). 62–73. 18 indexed citations

14.

Alexander, Jose, Dilbir S. Bindra, Marie A. Holahan, et al.. (1996). Investigation of (Oxodioxolenyl)methyl Carbamates as Nonchiral Bioreversible Prodrug Moieties for Chiral Amines. Journal of Medicinal Chemistry. 39(2). 480–486. 29 indexed citations

15.

Lynch, Joseph J., Jacquelynn J. Cook, Gary R. Sitko, et al.. (1995). Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.. Journal of Pharmacology and Experimental Therapeutics. 272(1). 20–32. 56 indexed citations

16.

Cook, Jacquelynn J., Gary R. Sitko, Bohumil Bednář, et al.. (1995). An Antibody Against the Exosite of the Cloned Thrombin Receptor Inhibits Experimental Arterial Thrombosis in the African Green Monkey. Circulation. 91(12). 2961–2971. 78 indexed citations

17.

Ramjit, Denise, Joseph J. Lynch, Gary R. Sitko, et al.. (1993). Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.. Journal of Pharmacology and Experimental Therapeutics. 266(3). 1501–1511. 26 indexed citations

18.

Sitko, Gary R., et al.. (1992). Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.. Circulation. 85(2). 805–815. 113 indexed citations

19.

Reilly, Christopher, E. J. Mayer, Gary R. Sitko, et al.. (1991). The effect of exogenous plasminogen activator inhibitor - 1 in a canine model of occlusive thrombus formation. Fibrinolysis and Proteolysis. 5(2). 99–104. 3 indexed citations

20.

Shebuski, Ronald J., et al.. (1990). Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.. Circulation. 82(1). 169–177. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact